AG
SYRS

Advisor Group’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Advisor Group’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-100
Closed -$12K – 5268
2018
Q3 		$12K Hold
100
– – ﹤0.01% 4201
2018
Q2 		$10K Sell
100
-25
-20% -$3.1K ﹤0.01% 4087
2018
Q1 		$16K Hold
125
– – ﹤0.01% 3828
2017
Q4 		$12K Buy
125
+75
+150% +$10.1K ﹤0.01% 4006
2017
Q3 		$7K Buy
+50
New +$9.4K ﹤0.01% 4155

Other funds holding SYRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Advisor Group's SYRS Position: Q4 2018 in Review

Advisor Group sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q4 2018, closing a stake of 100 shares — an estimated $12K sold.

Advisor Group first reported a position in SYRS in Q3 2017 and held it in 5 quarters. The position peaked at $16K in Q1 2018. 68 funds tracked by Wall St. Rank hold SYRS as of Q4 2018.

  • Advisor Group reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Advisor Group sold 100 Syros Pharmaceuticals, Inc. Common Stock shares in Q4 2018, an estimated $12K.
  • Advisor Group first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 5 quarters.
  • Advisor Group's Syros Pharmaceuticals, Inc. Common Stock position peaked at $16K in Q1 2018.
  • 68 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q4 2018.

Based on Advisor Group's 13F filing for Q4 2018, filed 11 Feb 2019.